Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 7 Genitourinary 5 Thoracic 4 Other hematologic neoplasm 3 Lymphoid 3 Breast 3 Gynecologic 2 Dermatologic 2 Tumor-Agnostic 1 Sarcoma 1 Plasma cell 1 Other solid neoplasm 1 Myeloid 1 Head & Neck 1 Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

Oxaliplatin 1409 Fluorouracil 1298 Capecitabine 1085 Gemcitabine 1042 Leucovorin 928 Irinotecan 815 Bevacizumab 803 Cisplatin 666 Radiotherapy 535 Cetuximab 469 pembrolizumab 428 Paclitaxel 389 Nivolumab 336 130-nm albumin-bound paclitaxel 322 Drug Therapy 314 Docetaxel 286 S 1 (combination) 273 Sorafenib 266 Folfox protocol 261 Albumin-Bound Paclitaxel 259 sintilimab 211 durvalumab 209 Surgical Procedures, Operative 203 tislelizumab 202 Radiosurgery 202 lenvatinib 201 apatinib 198 Carboplatin 186 Magnetic Resonance Spectroscopy 181 regorafenib 180

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Valacyclovir × Gastrointestinal × Clear all

NCT00638612 2023-08-25

PaTK01

Candel Therapeutics, Inc.

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡